Regeneron's Earnings Took A Big Tax Hit, And Still Pounded Forecasts

分组1 - Regeneron Pharmaceuticals reported adjusted earnings of $11.83 per share and $3.75 billion in third-quarter sales, exceeding analysts' expectations of $9.65 per share and $3.59 billion in sales [1][2] - The company's third-quarter earnings were impacted by a tax charge of 68 cents, yet still surpassed forecasts [1] - In the year-earlier period, Regeneron earned $12.46 per share on $3.72 billion in sales, indicating a slight decline in earnings year-over-year [2] 分组2 - Following the earnings report, Regeneron stock advanced more than 4% in premarket trades, reaching $610.80 [2] - The performance of Regeneron is contrasted with other biotech stocks, such as Disc Medicine and Revolution Medicines, which also experienced significant stock price increases [4] - The overall biotech sector is showing volatility, with various companies experiencing sharp stock movements based on earnings and market news [6]